The positron emission tomography with F18 17β-estradiol has the potential to benefit diagnosis and treatment of endometrial cancer

• 資料種別: 文書・図像類
• タイトル: The positron emission tomography with F18 17β-estradiol has the potential to benefit diagnosis and treatment of endometrial cancer
• 著者・編者: YOSHIDA, Yoshio; KUROKAWA, Tetsuji; SAWAMURA, Yoko; SHINAGAWA, Akiko; OKAZAWA, Hidehiko; FUJIBAYASHI, Yasuhisa; KOTSUJI, Fumikazu
• 著者標目: YOSHIDA, Yoshio; KUROKAWA, Tetsuji; SAWAMURA, Yoko; SHINAGAWA, Akiko; OKAZAWA, Hidehiko; FUJIBAYASHI, Yasuhisa; KOTSUJI, Fumikazu
• 出版事項: Elsevier
• 出版年月日等: 2007-03
• 出版年（W3CDTF）: 2007-03
• タイトル（掲載誌）: Gynecologic oncology
• 巻号年月日等（掲載誌）: 104 3
• 掲載巻: 104
• 掲載号: 3
• 掲載ページ: 764-766
• 本文の言語コード: eng
• 件名標目: FES-PET; Endometrial cancer; Endocrine treatment
• 対象利用者: 一般
• 一般注記: Background. The positron emission tomography (PET) with F18 17β-estradiol (FES) has good imaging for assessment of estrogen receptor in breast cancer. Case. We report on a 30-year-old woman who desired to preserve her fertility with well-differentiated endometrial adenocarcinoma. Before hormone treatment was started, FES-PET showed increased uptake of endometrium, magnetic resonance imaging (MRI) showed thickness and F- 18 fluorodeoxyglucose (FDG)-PET showed increased uptake. FES-PET after 3 months showed remaining FES uptake, but there were no abnormal findings on MRI and FDG-PET. Hysteroscopy showed remaining adenocarcinoma. After additional treatment, FES-PET showed a therapeutic response, and hysteroscopy showed no abnormal finding. Conclusions. To our knowledge, this is the first report that FES-PET has the potential to provide more useful information than did FDG-PET about the hormone therapy.
• オンライン閲覧公開範囲: 限定公開
• 関連情報（DOI）: 10.024
• 連携機関・データベース: 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）; https://irdb.nii.ac.jp
• 提供元機関・データベース: 福井大学 : 福井大学学術機関リポジトリ